Pregabalin in the discontinuation of long‐term benzodiazepines' use
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: Tolerance, dependence, and adverse effects on cognitive functions are well‐known consequences of long‐term use of benzodiazepines (BDZ), especially at high doses, raising thorny therapeutic problems in their discontinuation. One promising pharmacological agent in BDZ discontinuation might be the newer anti‐epileptic pregabalin, already successfully tested in the treatment of anxiety disorders. Methods: We report on a sample of 15 patients with long‐term, mostly high‐dose dependence from BDZ, treated with pregabalin in an open‐label study at doses 225–900 mg. Results: All patients discontinued successfully BDZ in 3–14 weeks, moreover with a significant reduction of their previous anxiety levels under BDZ. In addition, patients showed also a significant amelioration in their cognitive functioning. Pregabalin's side‐effects were mild and transient, lasting only during the first 2 weeks of treatment. Conclusion: Although preliminary, our findings suggest that pregabalin may be one new promising agent in the treatment of BDZ dependence. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 1×
“Long-term benzodiazepine (BDZ) use leads to tolerance and dependence, affecting also adversely users’ cognitive functioning (Ashton, 2005; Golombok et al., 1988; Rickels et al., 1999; Stewart, 2005).”
BackgroundCognitive impairment in long-term benzodiazepine users
Golombok, S., Moodley, P., & Lader, M. (1988) · Psychological Medicine · doi:10.1017/s0033291700007911 · Cited by 167 · cited 1×
“Long-term benzodiazepine (BDZ) use leads to tolerance and dependence, affecting also adversely users’ cognitive functioning (Ashton, 2005; Golombok et al., 1988; Rickels et al., 1999; Stewart, 2005).”
BackgroundRickels, K., Lucki, I., Schweizer, E., Garcia-Espana, F., & Case, W. G. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00003 · Cited by 49 · cited 1×
“Long-term benzodiazepine (BDZ) use leads to tolerance and dependence, affecting also adversely users’ cognitive functioning (Ashton, 2005; Golombok et al., 1988; Rickels et al., 1999; Stewart, 2005).”
Background
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Hadley, S. J., Mandel, F. S., & Schweizer, E. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111405360 · Cited by 66
Bobes, J., Rubio, G., Terán, A., Cervera, G., López-Gómez, V., Vilardaga, I., & Pérez, M. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2010.12.004 · Cited by 57
Carrus, D., & Schifano, F. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318272864d · Cited by 49
Bramness, J. G., Sandvik, P., Engeland, A., & Skurtveit, S. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00590.x · Cited by 37
Benzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Metadata
- Authors
- Oulis, P., Konstantakopoulos, G., Kouzoupis, A. V., Masdrakis, V. G., Karakatsanis, N. A., Karapoulios, E., Kontoangelos, K. A., & Papadimitriou, G. N.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2008-03-18
- Volume
- 23
- Issue
- 4
- Pages
- 337-340
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2035246885
- Cited by
- 39
- References
- 3
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.